EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Bebtelovimab: The FDA-approved Monoclonal Antibody for Treating Patients with Mild-to-Moderate COVID-19

Pouya Safarzadeh Kozani, Mehdi Sheikhi, Narges Baharifar, Setareh Dashti Shokoohi, Sara Sheikhi, Seyed Mohamad Javad Mirarefin, Pooria Safarzadeh Kozani, Abdolkarim Sheikhi

Trends in Medical Sciences · 2022

DOI: 10.5812/tms-130706 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Trends in Medical Sciences, 2022. Verfasst von Pouya Safarzadeh Kozani und 7 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 6 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Kozani, P. S., Sheikhi, M., Baharifar, N., Shokoohi, S. D., Sheikhi, S., Mirarefin, S. M. J., Kozani, P. S., & Sheikhi, A. (2022). Bebtelovimab: The FDA-approved Monoclonal Antibody for Treating Patients with Mild-to-Moderate COVID-19. Trends in Medical Sciences. https://doi.org/10.5812/tms-130706

Vancouver

Kozani PS, Sheikhi M, Baharifar N, Shokoohi SD, Sheikhi S, Mirarefin SMJ, et al. Bebtelovimab: The FDA-approved Monoclonal Antibody for Treating Patients with Mild-to-Moderate COVID-19. Trends in Medical Sciences. 2022. doi:10.5812/tms-130706

BibTeX
@article{Kozani2022,
  author = {Kozani, Pouya Safarzadeh and Sheikhi, Mehdi and Baharifar, Narges and Shokoohi, Setareh Dashti and Sheikhi, Sara and Mirarefin, Seyed Mohamad Javad and Kozani, Pooria Safarzadeh and Sheikhi, Abdolkarim},
  title = {Bebtelovimab: The FDA-approved Monoclonal Antibody for Treating Patients with Mild-to-Moderate COVID-19},
  journal = {Trends in Medical Sciences},
  year = {2022},
  doi = {10.5812/tms-130706}
}
Kostenlos starten →